Kyoto University iPS Cell Research Foundation
Basic information
- Head office
- Chief executive
- Capital
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- 2019-09-06
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| 日本骨髄バンク |
Network
History
Cell preparation facility (FiT) completed within the Kyoto University iPS Cell Research Institute, a national university corporation.
Initiated request for research participation from individuals who cooperated with platelet component donation at two Japanese Red Cross Society blood donation sites (Osaka and Kyoto).
Obtained the first Japanese approval as a cell culture and processing facility under the Regenerative Medicine Safety Assurance Act, Facility No.: FA5150001.
Commenced the first provision of an iPS cell stock.
Under research cooperation with the Japanese Red Cross Society and the Japan Bone Marrow Bank, began requesting research participation from individuals newly registering as donors with the bone marrow bank.
Cell preparation facility (FiT2) completed within the 3rd Research Building of the Kyoto University iPS Cell Research Institute, a national university corporation.
Reobtained approval as a cell culture and processing facility under the Regenerative Medicine Safety Assurance Act, Facility No.: FA5170003.
Established the General Incorporated Foundation Kyoto University iPS Cell Research Foundation.
Transitioned to the Public Interest Incorporated Foundation (Cabinet Office certified) Kyoto University iPS Cell Research Foundation.
Reobtained approval as a cell culture and processing facility under the Regenerative Medicine Safety Assurance Act, Facility No.: FA5200001.
Obtained manufacturing license (general category) for regenerative medicine products under the Pharmaceutical and Medical Device Act (PMD Act), License No.: 26FZ110001.
Reobtained approval as a cell culture and processing facility under the Regenerative Medicine Safety Assurance Act, Facility No.: FA5200001.
Reobtained manufacturing license (general category) for regenerative medicine products under the Pharmaceutical and Medical Device Act (PMD Act), License No.: 26FZ110001.
News
There is no news.